• Explore /
  • Poster
  • / FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (<em>FGFR2</em>) fusions/rearrangements.

FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.

Abstract Poster

Authors

Teresa Macarulla

Teresa Macarulla

Department of Medical Oncology, Vall d´Hebrón University Hospital, Vall d´Hebrón Institute of Oncology (VHIO), Barcelona, Spain

Teresa Macarulla , Takashi Mizuno , Giovanni Brandi , Jin Li , Ming-Huang Chen , Jung Hun Kang , Kathia Cristina Abdalla , Piotr Jan Wysocki , Nuno Couto , Bailey Anderson , Hamdy Elsayed , Parvez Mantry

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05727176

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS572)

DOI

10.1200/JCO.2024.42.3_suppl.TPS572

Abstract #

TPS572

Poster Bd #

P1

Abstract Disclosures

Similar Posters

First Author: Joon Oh Park

First Author: Junji Furuse

First Author: Milind M. Javle

First Author: Shubham Pant